Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
09:42pm, Wednesday, 08'th May 2024
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills – Chief Executive Officer Curran Simpso
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
06:40pm, Wednesday, 08'th May 2024
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $1.53 per share a year ago.
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
04:05pm, Wednesday, 08'th May 2024
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) Dose level 2 selected a
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
07:05am, Wednesday, 01'st May 2024
ROCKVILLE, Md. , May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m.
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
07:05am, Wednesday, 24'th Apr 2024
ROCKVILLE, Md. , April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Mon
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
07:05am, Thursday, 28'th Mar 2024
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical chal
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
04:05pm, Wednesday, 27'th Mar 2024
ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 202
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
11:53am, Monday, 11'th Mar 2024
Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Monday, 11'th Mar 2024
ROCKVILLE, Md. , March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Leerink Partners 2024 Global Biopharma Co
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
11:20pm, Wednesday, 06'th Mar 2024
ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, tod
REGENXBIO Announces Proposed Public Offering of Common Stock
04:10pm, Wednesday, 06'th Mar 2024
ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an und
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
12:36pm, Wednesday, 06'th Mar 2024
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
07:05am, Tuesday, 05'th Mar 2024
New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression Patient aged 12 years at dosing had expression level at 75.7% of control Early evidence of st
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
04:57pm, Thursday, 29'th Feb 2024
Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D.
REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript
09:45pm, Tuesday, 27'th Feb 2024
REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript
